Additional chromosomal abnormalities prognostic for CML
Additional chromosomal abnormalities can be used to create two prognostic groups of patients with chronic myeloid leukaemia, suggests research published in Blood. (Source: MedWire News)
Source: MedWire News - April 20, 2016 Category: Consumer Health News Tags: Chronic myeloid leukaemia Source Type: news
UCLA scientists pinpoint cancer gene responsible for neuroendocrine prostate cancer
Scientists at the UCLA Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research have discovered that a protein produced by a cancer gene leads to the development of a deadly, late-stage form of prostate cancer called neuroendocrine prostate cancer. The discovery could be a significant step toward a more effective treatment.
The findings, which were published in the journal Cancer Cell, are particularly important because neuroendocrine prostate cancer does not respond to standard treatments, and men who are diagnosed with the disease typically live for less than a year afterward. Up to one-quarter of t...
Source: UCLA Newsroom: Health Sciences - March 31, 2016 Category: Universities & Medical Training Source Type: news
New hope for a type 2 diabetes cure
The cancer treatment drug Imatinib, otherwise known as Gleevec is approved to treat various forms of cancer, mostly notably chronic myeloid leukemia (CML). However, researchers have stumbled onto another possible use for it, curing type 2 diabetes. The team - made up of scientists from the Scripps Research Institute in United States, South Korea-based company Hyndai Pharm Co., Ltd., the Seoul National University, and Ulsan National Institute of Science and Technology (UNIST) (Source: World Pharma News)
Source: World Pharma News - March 30, 2016 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news
Secondary non-Hodgkin’s lymphoma a concern for CML patients using TKIs
Patients with chronic myeloid leukaemia who use the tyrosine kinase inhibitor imatinib may be three to four times more likely to develop non-Hodgkin’s lymphoma than the general population, study findings indicate. (Source: MedWire News)
Source: MedWire News - March 19, 2016 Category: Consumer Health News Tags: Oncology Source Type: news
Vascular events in CML may not be linked to TKI therapy
The increased risk of vascular events observed among elderly patients with chronic myeloid leukaemia, compared with patients without cancer, may not be driven by tyrosine kinase inhibitor therapy, US researchers suggest. (Source: MedWire News)
Source: MedWire News - March 19, 2016 Category: Consumer Health News Tags: Chronic myeloid leukaemia Source Type: news
Real-life data show feasibility of imatinib discontinuation in CML
Italian research shows that long-term imatinib discontinuation is feasible outside of a clinical trial setting for patients with chronic myeloid leukaemia who achieve stable undetectable molecular disease with front-line treatment. (Source: MedWire News)
Source: MedWire News - March 19, 2016 Category: Consumer Health News Tags: Oncology Source Type: news
Using generic cancer drug could save many millions of dollars
With the expiration in January of the patent on Gleevec, the drug that 15 years ago changed chronic myeloid leukemia (CML) from a death sentence to a treatable illness, insurance companies and patients have the opportunity to realize huge cost savings, new Johns Hopkins Bloomberg School of Public Health research suggests. (Source: World Pharma News)
Source: World Pharma News - March 15, 2016 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news
Using generic cancer drug could save many millions of dollars
(Johns Hopkins University Bloomberg School of Public Health) With the expiration in January of the patent on Gleevec, the drug that 15 years ago changed chronic myeloid leukemia from a death sentence to a treatable illness, insurance companies and patients have the opportunity to realize huge cost savings, new Johns Hopkins Bloomberg School of Public Health research suggests. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - March 15, 2016 Category: Cancer & Oncology Source Type: news
Don’t lie down!
Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today’s challenges and opportunities. The Catalyst welcomes guest contributors, including patients, stakeholders, innovators and others, to share their perspectives and point of view. Views represented here may not be those of PhRMA, though they are no less key to a healthy dialogue on issues in health care today.
We’re pleased to host a guest blog from Jamie Pires, a chronic myelogenous leukemia patient and advocate. Hear more about Jamie’s story here.
As children, we fantas...
Source: The Catalyst - February 24, 2016 Category: Pharmaceuticals Authors: Guest Contributor Tags: Rare Diseases Leukemia Rare Disease Day Source Type: news
Mtss1 ‘tumour suppressor’ for CML
medwireNews: The metastasis suppressor 1 protein acts a tumour suppressor in chronic myeloid leukaemia stem cells, reveals research published in Leukemia. (Source: MedWire News)
Source: MedWire News - February 19, 2016 Category: Consumer Health News Tags: Chronic myeloid leukaemia Source Type: news
Vascular Occlusion Risk Reviewed For CML New-Generation TKIs
A meta-analysis highlights the significantly increased risk of vascular occlusive events in patients with chronic myeloid leukaemia using some new-generation BCR–ABL tyrosine kinase inhibitors compared with use of imatinib. (Source: MedWire News)
Source: MedWire News - February 19, 2016 Category: Consumer Health News Tags: Chronic myeloid leukaemia Source Type: news
Allo-HSCT Non-Relapse Related Mortality Reduction Revealed
A reduction in the risks of infection- and organ failure-related death has driven an improvement in non-relapse mortality among recipients of allogeneic haematopoietic stem cell transplantation, Japanese research suggests. (Source: MedWire News)
Source: MedWire News - February 19, 2016 Category: Consumer Health News Tags: Chronic myeloid leukaemia Source Type: news
New assay detects persistent disease in leukemia patients thought to be in remission
A new study describes a new personalized DNA-based digital assay that detects persistent chronic myeloid leukemia in 81 percent of samples taken from a group of patients thought to be in remission. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - February 5, 2016 Category: Science Source Type: news
New assay detects persistent disease in leukemia patients thought to be in remission
(Elsevier Health Sciences) A study in The Journal of Molecular Diagnostics describes a new personalized DNA-based digital assay that detects persistent chronic myeloid leukemia in 81 percent of samples taken from a group of patients thought to be in remission. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 5, 2016 Category: Cancer & Oncology Source Type: news
Cancer drug helps combat asthma in mice
(Wiley) In a mouse model of allergic asthma, dasatinib -- an enzyme inhibitor approved for the treatment of chronic myelogenous leukemia -- reduced inflammation, enhanced airway repair, and improved lung mechanics. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 1, 2016 Category: Cancer & Oncology Source Type: news
